Maravai Lifesciences Holdings Inc. (MAR)
XDUS 
Summary
MAR Chart
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
Maravai Lifesciences Holdings Inc. (MAR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Maravai Lifesciences Holdings Inc. ever had a stock split?
Maravai Lifesciences Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bernd Brust CEO | XDUS Exchange | US56600D1072 ISIN |
| US Country | 415 Employees | - Last Dividend | - Last Split | 20 Nov 2020 IPO Date |
Overview
Maravai LifeSciences Holdings, Inc. is a prominent player in the life sciences industry, dedicated to providing a comprehensive range of products that facilitate the development of drug therapies, diagnostics, and novel vaccines, in addition to supporting research on human diseases on a global scale. Established in 2020 and based in San Diego, California, Maravai LifeSciences serves a diverse clientele that includes biopharmaceutical companies, life sciences research organizations, academic research institutions, and in vitro diagnostics companies. The company strategically operates through two main segments: Nucleic Acid Production and Biologics Safety Testing, catering to the critical phases of biopharmaceutical development with its innovative product offerings.
Products and Services
- Nucleic Acid Production
- Biologics Safety Testing
This segment is key to Maravai LifeSciences, providing essential products for gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. It includes the production and sale of reagents for the chemical synthesis, modification, labeling, and purification of DNA and RNA. Key offerings comprise messenger RNA, oligonucleotides, oligonucleotide building blocks, custom enzyme development and manufacturing, along with CleanCap capping technology, which is instrumental in the success of these revolutionary therapies and diagnoses.
Focusing on the safety aspect of biopharmaceutical production, this segment delivers analytical products designed for biologic manufacturing process development. It includes custom product-specific development, antibody and assay development services tailored to clients' needs. The segment also offers Host Cell Protein (HCP) ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and bespoke services. These products are crucial for ensuring the purity and efficacy of biopharmaceutical products by detecting impurities and contaminants during production stages.
